Endo, Inc. Highlights Promising Study Results for Plantar Fibromatosis Treatment
MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has unveiled promising data from its Phase 2 clinical study of collagenase clostridium histolyticum (CCH) in treating plantar fibromatosis, presented at the American Orthopaedic …
Endo, Inc. Highlights Promising Study Results for Plantar Fibromatosis Treatment Read More